Diabetes and bone. Focus on DPP-4 inhibitors

Медицинский совет

A. Y. Babenko¹  V. S. Nikitin¹  T. L. Karonova¹ 

[1] Federal North-West Medical Research Centre Northw named after V.A. Almazov;

关键词: сахарный диабет, остеопороз, костный метаболизм, противодиабетические препараты, метформин;    препараты сульфонилмочевины;    ингибиторы натрий-глюкозного котранспортера 2-го типа;    тиазолидиндионы;    ингибиторы дипепидил-пептидазы-4б;    агонисты рецепторов глюкагоноподобного пептида-1;    diabetic nephropathy;    osteoporosis;    bone metabolism;    antidiabetic drugs;    metformin;    sulfonylureas;    thiazolidinediones;    dipeptidyl peptidase-4 inhibitors;    glucagon-like peptide-1 receptor agonists;    sodium-glucose cotransporter 2 inhibitors;   

DOI  :  10.21518/2079-701X-2015-17-108-113

来源: DOAJ

【 摘 要 】

Pathology of bone homeostasis in diabetes mellitus (DM) is a significant problem that must be considered when selecting anti-diabetic therapy. Many anti-diabetic drugs have a specific effect on bone homeostasis which should be taken into account when selecting treatment for type 2 diabetes, especially in patients at high risk of osteoporosis. This review discusses mechanisms of impact on bone metabolism and fracture risks of DM and various groups of antidiabetic drugs, focusing on new groups of drugs included in the Russian algorithms over the past decade (GLP-1 receptor agonists, DPP-4 inhibitors, sodium-glucose cotransporter 2 inhibitors). It can be useful to both researchers and clinicians who are striving to offer the therapy of choice to their patients today.

【 授权许可】

Unknown